Score the GAD-7 generalized anxiety disorder questionnaire. Includes severity interpretation, treatment recommendations, item-level analysis, symptom domains, and evidence-based treatment comparison.
The GAD-7 (Generalized Anxiety Disorder 7-item) Calculator implements the most widely used standardized screening tool for generalized anxiety disorder. Developed by Spitzer, Kroenke, Williams, and Löwe (2006), the GAD-7 is a brief, validated self-report questionnaire that assesses the frequency of core anxiety symptoms over the preceding two weeks.
The GAD-7 demonstrates excellent psychometric properties: internal consistency (Cronbach's α = 0.92), test-retest reliability (ICC = 0.83), sensitivity of 89%, and specificity of 82% for detecting generalized anxiety disorder at the standard cutoff of ≥10. It is recommended as a screening tool by the United States Preventive Services Task Force (USPSTF), the American Psychiatric Association, and is embedded in the electronic health records of most major health systems.
Beyond GAD screening, the GAD-7 is also sensitive to panic disorder, social anxiety disorder, and post-traumatic stress disorder, making it a useful general anxiety screener. This calculator provides severity grading (minimal, mild, moderate, severe), item-level analysis to identify dominant symptoms, cognitive versus somatic domain breakdown, and evidence-based treatment recommendations keyed to severity level.
Anxiety disorders affect ~18% of adults yet are underdiagnosed in primary care. The GAD-7 takes 2–3 minutes to administer, requires no specialized training to interpret, and provides a quantitative severity measure for tracking treatment response. It is the companion to the PHQ-9 (depression screening) and together they cover the two most common mental health conditions.
GAD-7 Score = Sum of 7 items (each scored 0–3) Scoring key: 0 = Not at all 1 = Several days 2 = More than half the days 3 = Nearly every day Total range: 0–21 Cutoffs: • 0–4: Minimal • 5–9: Mild • 10–14: Moderate (diagnostic threshold for GAD) • 15–21: Severe anxiety
Result: GAD-7 = 12 — Moderate anxiety. GAD diagnosis probable. Recommend CBT and/or SSRI.
A score of 12 falls in the moderate range (10–14). Items Q1–Q3 scored highest (worry/nervousness), indicating dominant cognitive anxiety symptoms. This exceeds the diagnostic screening cutoff of 10, suggesting a high likelihood of GAD that warrants diagnostic evaluation. Functional impairment was rated "very difficult," reinforcing clinical significance. First-line treatment: CBT or SSRI/SNRI monotherapy; combination for more severe cases.
The USPSTF (2023) recommends screening for anxiety in all adults aged 19–64 in primary care settings. The GAD-7 is the most studied and widely adopted tool for this purpose. Implementation typically follows a two-step approach: GAD-2 (first 2 items) as an ultra-brief screener, followed by the full GAD-7 if GAD-2 ≥3. This approach has 86% sensitivity and 83% specificity while reducing assessment burden. Most electronic health records support automated GAD-7 scoring and trending.
Measurement-based care (MBC) uses standardized symptom measures like GAD-7 to guide treatment decisions at every visit. Studies show MBC improves anxiety outcomes by 15–25% compared to usual care. The GAD-7 enables: treatment response tracking (≥5-point change = clinically meaningful), medication titration decisions based on objective data, identification of non-responders for treatment modification, and shared decision-making with patients who can see their progress visually.
First-line medications for GAD: SSRIs (sertraline, escitalopram, paroxetine) and SNRIs (venlafaxine XR, duloxetine) have the strongest evidence. Typical trial: 8–12 weeks at adequate dose before determining response. Buspirone is effective but slower onset (2–4 weeks). Pregabalin is first-line in European guidelines but not FDA-approved for GAD in the US. Benzodiazepines provide rapid relief but carry dependence risk and are not recommended for long-term use. Hydroxyzine is sometimes used for acute anxiety without dependence risk. Gabapentin has limited evidence but is sometimes used off-label.
A score of 10+ indicates a high probability of clinically significant generalized anxiety disorder. At this cutoff, the GAD-7 has 89% sensitivity and 82% specificity for GAD. However, the GAD-7 is a screener, not a diagnostic tool — a score ≥10 should prompt a full clinical assessment including: duration of symptoms (≥6 months for GAD per DSM-5), functional impairment, medical causes (hyperthyroidism, caffeine, medications), substance use, and other anxiety disorders (panic, social, OCD). About 74% of patients scoring ≥10 meet diagnostic criteria for GAD.
For screening: annually in primary care, or when anxiety is clinically suspected. For treatment monitoring: every 2–4 weeks during initial treatment phase, then monthly during maintenance. A clinically meaningful change is ≥5 points. GAD-7 scores should be documented in the medical record alongside treatment modifications. Some clinics administer GAD-7 at every visit as part of vital signs ("measurement-based care"). The USPSTF recommends anxiety screening for all adults under 65.
No — despite its name, the GAD-7 is sensitive to other anxiety disorders as well. Operating characteristics at ≥10: GAD (sensitivity 89%, specificity 82%), panic disorder (sensitivity 74%), social anxiety disorder (sensitivity 72%), and PTSD (sensitivity 66%). This makes it a reasonable general anxiety screener, though disorder-specific instruments (PHQ-PD for panic, SPIN for social anxiety, PCL-5 for PTSD) are more accurate for those specific conditions. The GAD-7 is not designed for OCD, specific phobias, or separation anxiety.
GAD-7 (anxiety) and PHQ-9 (depression) are companion instruments developed by the same team using similar methodology. They are frequently administered together because anxiety-depression comorbidity is extremely common (~60%). The combination takes about 5 minutes and screens for the two most prevalent mental health conditions in primary care. Scoring patterns provide useful clinical information: predominant anxiety (GAD-7 >> PHQ-9) suggests anxiolytic-focused treatment, while co-elevated scores suggest combined treatment. Both can track treatment response independently.
Consider psychiatric referral when: GAD-7 ≥15 (severe anxiety), inadequate response to 2 adequate trials of first-line medications (8–12 weeks each), significant comorbidity (depression, substance use, personality disorder), suicidal ideation, diagnostic uncertainty (which specific anxiety disorder?), pregnancy/lactation (medication safety concerns), complex medication interactions, or patient preference for specialist care. In practice, CBT with a trained therapist is the most effective referral for most anxiety disorders and can be accessed through psychology, psychiatry, or behavioral health integration programs.
The GAD-7 has been translated and validated in 50+ languages and demonstrates good cross-cultural properties. However, cultural factors affect anxiety expression: some cultures emphasize somatic symptoms (headache, GI distress, fatigue) over cognitive/emotional symptoms (worry, nervousness). Patients from somatically-oriented cultures may score lower on GAD-7 despite significant anxiety. Additionally, the 2-week recall period may not capture intermittent or culturally-patterned anxiety. The GAD-7 has been validated in diverse populations including East Asian, Latin American, Middle Eastern, and African cohorts.